Latest Regulatory Challenges News

Mirrabooka Investments posted a 63.6% profit increase to $13 million for FY26 but saw its portfolio return lag the benchmark. The company declared a 14 cents fully franked dividend and welcomed Alison Gibson as new CEO following Mark Freeman's retirement.

Entropy Neurodynamics (ASX:ENP) reported a 30% rise in income and a narrower loss for FY26, driven by clinical progress in its IV-infused psilocin therapy TRP-8803, including promising Phase 2 results in Binge Eating Disorder and a new multi-indication basket study.

PEXA Group delivered a solid FY26 with 7% revenue growth and a return to profitability, while facing a regulatory pricing review that could reshape its future investment capacity.

Careteq Limited (ASX: CTQ) reported a $398K net loss for FY26 amid a strategic reset that included selling its Embedded Health Solutions business and repaying all debt. The company now pivots fully to growing its HMR Referrals platform with $3.19 million cash on hand.

Paladin Energy Ltd (ASX:PDN) reversed prior losses with a net profit of US$5.3 million in FY2026, driven by a strong ramp-up of uranium production at Namibia's Langer Heinrich Mine and regulatory progress at its Canadian Patterson Lake South Project.

Vysarn Limited reported a robust 31.5% increase in revenue to $140 million for FY2026, driven by strong performances across its industrial, advisory, and technology segments. The company is accelerating its national footprint with strategic acquisitions and progressing the Kariyarra Water Scheme.

Winton Land reported a 120% rise in net profit to $22.7 million in FY26, driven by increased residential settlements and full-year trading at its hospitality venues, despite economic headwinds and leadership changes.

Coles Group reported a 2.8% rise in FY26 sales revenue to $45.58 billion, driven by supermarket growth and digital gains, while navigating $235 million in regulatory provisions.

City Chic Collective’s FY26 underlying EBITDA surged 92% to $12.3 million, driven by ANZ growth and cost discipline, while group revenue fell 3.1%. The company enters FY27 with a stronger margin profile and a clean inventory position amid ongoing US tariff challenges.

Aurora Labs posted a 36% increase in net loss to $5.1 million for FY2026 despite securing key defence contracts and partnerships. The company is transitioning from R&D to early commercialisation of its micro gas turbine propulsion systems, backed by a $5.5 million capital raise and government grants.

Telix Pharmaceuticals returned to profit in H1 2026, driven by strong U.S. sales of Illuccix and Gozellix, a $40 million upfront from Regeneron collaboration, and expanded R&D investment.

Dusk Group delivered record FY26 sales and underlying EBIT growth, driven by product rejuvenation and online momentum, while preparing for international expansion amid ACCC proceedings.